R&D News | pharmaphorum

News

Roche makes obesity play with $2.7bn deal to buy Carmot

Roche has agreed a deal to acquire US biotech Carmot Therapeutics that, if consummated, will thrust it into the increasingly competitive market for incretin-based therapie

News

AstraZeneca links with Absci on AI for biologics discovery

AstraZeneca has agreed a deal worth up to $247 million with US generative artificial intelligence (GenAI) company Absci that will focus on the discovery of a new antibody-

News

MSD, Amgen back patient data specialist Culmination Bio

The venture capital arms of MSD and Amgen have provided $10 million in funding to Culmination Bio, a Utah start-up that aims to build the largest disease-agnostic patient

News

AZ drops two trials aimed at expanding Lokelma’s label

AstraZeneca has decided to abandon two phase 3 trials of its drug to reduce high levels of potassium in the blood (hyperkalaemia) – Lokelma – in patients with kidney disea

News

Cybin preps for ph3 as psychedelic clears depression trial

Cybin has unveiled phase 2 results with its psychedelic medicine for major depressive disorder, which it says support moving the drug into a phase 3 programme.

News

AbbVie agrees $10.1bn deal to buy ImmunoGen

AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovar

Roche makes obesity play with $2.7bn deal to buy Carmot

AstraZeneca links with Absci on AI for biologics discovery

MSD, Amgen back patient data specialist Culmination Bio

AZ drops two trials aimed at expanding Lokelma’s label

Cybin preps for ph3 as psychedelic clears depression trial

AbbVie agrees $10.1bn deal to buy ImmunoGen

FDA grants three priority vouchers to psychedelics

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks